GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dogwood Therapeutics Inc (NAS:DWTX) » Definitions » Debt-to-Equity

DWTX (Dogwood Therapeutics) Debt-to-Equity : 0.24 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Dogwood Therapeutics Debt-to-Equity?

Dogwood Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.05 Mil. Dogwood Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $15.54 Mil. Dogwood Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $64.28 Mil. Dogwood Therapeutics's debt to equity for the quarter that ended in Dec. 2024 was 0.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dogwood Therapeutics's Debt-to-Equity or its related term are showing as below:

DWTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.74   Med: -0.25   Max: 0.24
Current: 0.24

During the past 7 years, the highest Debt-to-Equity Ratio of Dogwood Therapeutics was 0.24. The lowest was -0.74. And the median was -0.25.

DWTX's Debt-to-Equity is ranked worse than
59.27% of 1014 companies
in the Biotechnology industry
Industry Median: 0.14 vs DWTX: 0.24

Dogwood Therapeutics Debt-to-Equity Historical Data

The historical data trend for Dogwood Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dogwood Therapeutics Debt-to-Equity Chart

Dogwood Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial - - - - 0.24

Dogwood Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.24

Competitive Comparison of Dogwood Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Dogwood Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dogwood Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dogwood Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dogwood Therapeutics's Debt-to-Equity falls into.


;
;

Dogwood Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dogwood Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Dogwood Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dogwood Therapeutics  (NAS:DWTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Dogwood Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dogwood Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Dogwood Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
44 Milton Avenue, Alpharetta, GA, USA, 30009
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Executives
William Pridgen director 44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan director, officer: Chief Executive Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh officer: VP of Finance 44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel director 44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer director 44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald officer: Vice President of Operations 44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau officer: Chief Medical Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch director 44 MILTON AVENUE, ALPHARETTA GA 30009